<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00019578</url>
  </required_header>
  <id_info>
    <org_study_id>990011</org_study_id>
    <secondary_id>99-C-0011</secondary_id>
    <secondary_id>CDR0000066758</secondary_id>
    <nct_id>NCT00019578</nct_id>
    <nct_alias>NCT00001791</nct_alias>
  </id_info>
  <brief_title>Stereotactic Radiosurgery in Treating Patients With Brain Tumors</brief_title>
  <official_title>Phase I Pilot Study of Stereotaxic Radiosurgery in Patients With Intracranial Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase I&#xD;
      trial to study the effectiveness of stereotactic radiosurgery in treating patients who have&#xD;
      brain tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Establish stereotaxic radiosurgery as a treatment technique at the National&#xD;
      Institute of Health in patients with intracranial neoplasms.&#xD;
&#xD;
      II. Assess the response rate, local control, time to progression, pattern of failure, and&#xD;
      magnetic resonance spectrographic data following this therapy in these patients.&#xD;
&#xD;
      PROTOCOL OUTLINE: All patients undergo stereotaxic head frame placement, followed by&#xD;
      stereotaxic radiosurgery on day 1. The dosage of radiation therapy administered is dependent&#xD;
      on the tumor diameter.&#xD;
&#xD;
      Patients are followed at 2 and 6 weeks and then every 3 months for 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL:&#xD;
&#xD;
      Up to 30 patients will be accrued for this study within 7-10 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1998</start_date>
  <completion_date type="Actual">May 2002</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Adult Central Nervous System Germ Cell Tumor</condition>
  <condition>Adult Malignant Meningioma</condition>
  <condition>Adult Medulloblastoma</condition>
  <condition>Adult Noninfiltrating Astrocytoma</condition>
  <condition>Adult Oligodendroglioma</condition>
  <condition>Adult Craniopharyngioma</condition>
  <condition>Adult Meningioma</condition>
  <condition>Brain Metastases</condition>
  <condition>Adult Ependymoma</condition>
  <condition>Adult Pineal Parenchymal Tumor</condition>
  <condition>Adult Brain Stem Glioma</condition>
  <condition>Adult Infiltrating Astrocytoma</condition>
  <condition>Mixed Gliomas</condition>
  <condition>Stage IV Peripheral Primitive Neuroectodermal Tumor</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sterotactic radiosurgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics-- Histologically proven intracranial tumor OR Pathologically&#xD;
        confirmed cancer with metastases to the brain OR Newly discovered brain lesions that are&#xD;
        amenable to stereotaxic biopsy No more than 3 measurable tumors Only 1 tumor more than 3 cm&#xD;
        in diameter that requires radiosurgery allowed No tumor more than 4 cm in diameter No tumor&#xD;
        that involves more than 50% of the brain stem --Prior/Concurrent Therapy-- Biologic&#xD;
        therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Concurrent&#xD;
        corticosteroids allowed Radiotherapy: Prior cranial radiotherapy allowed Surgery:&#xD;
        Radiosurgery to other nonstudy intracranial lesions allowed Prior biopsy and/or subtotal or&#xD;
        near-total resection allowed --Patient Characteristics-- Age: 18 and over Performance&#xD;
        status: Karnofsky 70-100% OR ECOG 0-2 Life expectancy: More than 3 months Hematopoietic:&#xD;
        WBC at least 3,000/mm3 Absolute granulocyte count at least 500/mm3 Hemoglobin at least 10&#xD;
        g/dL Platelet count at least 50,000/mm3 Hepatic: SGOT or SGPT no greater than 2.5 times&#xD;
        upper limit of normal (ULN) PT and PTT no greater than 1.5 times ULN No clinically&#xD;
        significant hepatic dysfunction Renal: Creatinine no greater than 1.3 times ULN&#xD;
        Cardiovascular: No clinically significant cardiac dysfunction Pulmonary: No clinically&#xD;
        significant pulmonary dysfunction Other: Not pregnant or nursing Negative pregnancy test No&#xD;
        clinically significant systemic illness or serious infection that would preclude study&#xD;
        compliance No other organ dysfunction that would preclude study compliance No history of&#xD;
        psychiatric disease No allergy to contrast agent Papilledema and motor or sensory deficits&#xD;
        allowed No contraindications to MRI (e.g., aneurysm clip, implanted neural stimulator,&#xD;
        implanted cardiac defibrillator, cochlear implant, ocular foreign body or implant, or&#xD;
        insulin pump)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Brian G. Fuller</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiation Oncology Branch</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>March 1, 2007</study_first_submitted>
  <study_first_submitted_qc>March 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2007</study_first_posted>
  <last_update_submitted>March 21, 2012</last_update_submitted>
  <last_update_submitted_qc>March 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2012</last_update_posted>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult brain tumor</keyword>
  <keyword>adult central nervous system germ cell tumor</keyword>
  <keyword>adult craniopharyngioma</keyword>
  <keyword>adult ependymoma</keyword>
  <keyword>adult infiltrating astrocytoma</keyword>
  <keyword>adult malignant meningioma</keyword>
  <keyword>adult medulloblastoma</keyword>
  <keyword>adult meningioma</keyword>
  <keyword>adult noninfiltrating astrocytoma</keyword>
  <keyword>adult oligodendroglioma</keyword>
  <keyword>adult pineal parenchymal tumor</keyword>
  <keyword>adult solid tumor</keyword>
  <keyword>body system/site cancer</keyword>
  <keyword>brain metastases</keyword>
  <keyword>brain tumor</keyword>
  <keyword>cancer</keyword>
  <keyword>central nervous system cancer</keyword>
  <keyword>genetic condition</keyword>
  <keyword>metastatic cancer</keyword>
  <keyword>mixed gliomas</keyword>
  <keyword>site, metastatic cancer</keyword>
  <keyword>solid tumor</keyword>
  <keyword>stage IV peripheral primitive neuroectodermal tumor</keyword>
  <keyword>stage/type, adult brain tumor</keyword>
  <keyword>unclassified/other cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Meningioma</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive, Peripheral</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Craniopharyngioma</mesh_term>
    <mesh_term>Adamantinoma</mesh_term>
    <mesh_term>Pinealoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

